Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
about
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyImpact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to dateAn observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemiaMolecular landscape and targeted therapy of acute myeloid leukemia
P2860
Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@en
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@nl
type
label
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@en
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@nl
prefLabel
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@en
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P1433
P1476
Blinatumomab for minimal resid ...... acute lymphoblastic leukemia.
@en
P2093
Christoph Faul
Dirk Nagorsen
Gerhard Zugmaier
Heinz-August Horst
Hendrik Wessels
Julia Stieglmaier
Max S Topp
Nicola Gökbuget
Vincent Haddad
Violaine Havelange
P2860
P304
P356
10.1182/BLOOD-2017-08-798322
P407
P50
P577
2018-01-22T00:00:00Z